Sigma Healthcare rerating rests on delivering $100m merger synergies

Sigma Healthcare (ASX: SIG) now turns on one fact above all others: the Chemist Warehouse merger has transformed a low-growth wholesaler into a scaled pharmacy retail and distribution group, and management has already lifted the expected synergy prize to $100m a year by FY29 from $60m. That upgrade, announced in October, was the clearest signal that the merged supply chain, store network and private-label portfolio can produce more profit than first assumed.

For investors, the valuation question is no longer whether the deal changed the business. It is whether Sigma Healthcare can keep converting scale into higher margins without stumbling on integration.

Over the past 12 months, the share price has been driven by that merger story and then by proof points. The biggest structural event was the completion of the Chemist Warehouse transaction in February 2025.

But the largest share price reaction likely came later, when management said on 22 October 2025 that annual synergies would be $100m rather than $60m. That was not a cosmetic change. It implied a much larger earnings base over time and suggested the distribution footprint, procurement and operating model had more room for consolidation than the market had pencilled in.

Revenue quality matters more here

The February 2026 half-year result then backed up the optimism. Revenue rose 14.9% to $5.5bn, normalised Earnings Before Interest and Tax (EBIT) increased 18.7% to $582.9m, and normalised net profit after tax climbed 19.2% to $392.0m. Those are strong numbers for a business that is still integrating a major merger.

Sigma Healthcare is now an integrated healthcare business with two engines. One is full-line pharmaceutical wholesale distribution through 13 domestic distribution centres plus operations in Ireland and New Zealand.

The other is retail pharmacy franchising, led by the Chemist Warehouse branded network and supported by Amcal, Discount Drug Stores and Optometrist Warehouse. It also earns from franchise fees, marketing services, generic medicines, owned and exclusive label products, and some lease income tied to franchise-related properties.

Why that matters is simple: this is no longer just a low-margin distributor moving boxes for pharmacies. The retail network drives volume, the wholesale arm fulfils that volume, and owned-label and generic products can lift gross margins. When the model works, each extra store opening and each increase in like-for-like sales can ripple through several profit lines at once.

Revenue quality matters more here

That is also why investors are paying close attention to network growth. In the first half of FY26, Sigma Healthcare added 13 domestic Chemist Warehouse stores to reach 550.

International network sales rose 24.5%, with 70 stores in New Zealand and 17 in Ireland. This growth engine is more repeatable than a one-off acquisition because it blends new stores, mature store sales, own-brand expansion and supply chain efficiency.

The single most important driver of Sigma Healthcare’s current valuation is confidence in synergy delivery. In our view, that sits ahead of simple sales growth because the market can already see the top-line momentum. The harder and more valuable question is how much of that revenue turns into sustainably higher earnings.

Management delivered $13.0m of early synergies in the first half and says it remains on track for $100m a year by FY29. The October announcement showed where some of that should come from.

The ePharmacy distribution centre in Victoria and Chemist Warehouse distribution

Sigma Healthcare said it would close the ePharmacy distribution centre in Victoria and Chemist Warehouse distribution centres in Port Adelaide and South Guildford, with volumes absorbed into Sigma Healthcare’s own sites. If those changes are handled well, the merged group should carry more volume through a simplified network, lowering unit costs.

This is the structural change. It should take years, not quarters, to fully play out. By contrast, some recent tailwinds are shorter term. GLP-1 medicine sales helped demand, but that uplift will eventually be cycled. Seasonal trading and working capital swings can also distort interim numbers. Investors should separate those temporary effects from the enduring value drivers of scale, procurement, store rollout and own-brand mix.

We think the owned and exclusive label portfolio is the second most important support for valuation. More than 400 new products were added in the half, helping category sales growth of 15.7%, while the Wagner generics range reached 39% of the recommended generics range. Products that Sigma Healthcare controls more directly can improve both differentiation and margin resilience.

the post-merger momentum story

The next six to 12 months matter because the market will want evidence that the post-merger momentum can continue without relying on easy wins.

Near-term catalysts include onboarding nine Chemist Warehouse pharmacies in Australia in the second half, adding 15 Amcal franchisees, opening 11 international Chemist Warehouse stores, and continuing the synergy program. There is also a New Zealand supply chain assessment and work to improve profitability in Ireland now that the distribution centre is fully functioning.

Those are credible levers, but they come with operational risk. Supply chain consolidation can save money, yet it can also disrupt service if inventory, freight or systems are mismanaged. International growth looks promising, but Ireland still needs to show better profitability, and the China store network closure program remains a distraction.

Technical conditions for the stock from here are fairly clear. Sigma Healthcare should strengthen further if second-half trading confirms domestic sales momentum, synergies keep tracking to plan, and margins continue to expand faster than revenue.

The final call from here

A strong update showing more store openings, stable service levels through distribution centre closures, and further progress in owned-label penetration would support another rerating. Net debt to normalised Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) of 0.6x also gives balance sheet room.

The stock would weaken materially if any of three things happen: synergies slip against guidance, supply chain consolidation creates service issues, or Ireland and other offshore operations absorb more capital without delivering returns. In our opinion, a material miss on margin progression would matter more than a modest sales miss, because the valuation case rests on proving the combined model is structurally more profitable.

The bull case is not hard to see. Sigma Healthcare has a dominant pharmacy retail brand in Chemist Warehouse, a large wholesale backbone, clear network expansion, an expanding owned-label range and a bigger-than-expected synergy pool.

That is the core judgment. Sigma Healthcare is no longer a story about whether the Chemist Warehouse deal works in principle. It is about whether the enlarged group can keep delivering enough hard numbers to justify a premium rating. For now, we believe it can, and that makes the stock a Buy.